|
市場調査レポート
商品コード
1459488
ジェネリック医薬品の世界市場 2024-2028Global Generic drugs Market 2024-2028 |
||||||
カスタマイズ可能
|
ジェネリック医薬品の世界市場 2024-2028 |
出版日: 2024年03月19日
発行: TechNavio
ページ情報: 英文 168 Pages
納期: 即納可能
![]() |
ジェネリック医薬品市場は2023-2028年に2,125億8,000万米ドル、予測期間中のCAGRは7.86%で成長すると予測されています。
当レポートでは、ジェネリック医薬品市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場を牽引しているのは、ブランド医薬品に代わる低コストの医薬品、創薬・市場開拓のアウトソーシングの増加、ブランド医薬品の特許切れ増加などです。
市場範囲 | |
---|---|
基準年 | 2024 |
終了年 | 2028 |
予測期間 | 2024-2028 |
成長モメンタム | 加速 |
前年比2024年 | 6.62% |
CAGR | 7.86% |
増分額 | 2,125億8,000万米ドル |
本調査では、RPA(ロボティック・プロセス・オートメーション)の登場が今後数年間のジェネリック医薬品市場成長を牽引する主要因の1つであると分析しています。また、市場ベンダー間のM&Aの上昇と病院所有のジェネリック医薬品の出現は、市場の大規模な需要につながります。
Exhibits:
The generic drugs market is forecasted to grow by USD 212.58 bn during 2023-2028, accelerating at a CAGR of 7.86% during the forecast period. The report on the generic drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by low-cost alternatives to branded medicines, increased outsourcing of drug discovery and development, and rising expiry of patents on branded drugs.
Technavio's generic drugs market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 6.62% |
CAGR | 7.86% |
Incremental Value | $212.58bn |
By Route Of Administration
By Type
By Geographical Landscape
This study identifies the advent of RPA (robotic process automation) as one of the prime reasons driving the generic drugs market growth during the next few years. Also, rising m and a among market vendors and the emergence of hospital-owned generics will lead to sizable demand in the market.
The report on the generic drugs market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading generic drugs market vendors that include Abbott Laboratories, Amgen Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Baxter International Inc., Biocon Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., PlantForm Corporation, Sanofi SA, STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the generic drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.